Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Metastatic NSCLC — Targetable Driver, First-Line

Metastatic NSCLC targetable driver on broad NGS EGFR ex19 / L858R EGFR exon 20 ins EGFR atypical ALK ROS1 BRAF V600E MET exon 14 RET fusion NTRK fusion KRAS G12C HER2 (ERBB2) Preferred Osimertinib FLAURA ↗ CNS Intensified Chemo + osimertinib FLAURA2 ↗ Chemo-free Amivantamab + lazertinib MARIPOSA ↗ CNS Targeted Amivantamab + chemo PAPILLON ↗ TKI Afatinib or osimertinib context-dependent ↗ Preferred Lorlatinib CROWN ↗ CNS Alternative Alectinib ALEX ↗ CNS TKI Entrectinib / repotrectinib TRIDENT-1 ↗ CNS Targeted Dabrafenib + trametinib or encorafenib + binimetinib ↗ TKI Capmatinib / tepotinib GEOMETRY ↗ TKI Selpercatinib / pralsetinib LIBRETTO-001 ↗ CNS Tumor-agnostic Larotrectinib / entrectinib NAVIGATE / STARTRK ↗ CNS Later-line Sotorasib / adagrasib CodeBreaK 200 ↗ ADC Trastuzumab deruxtecan DESTINY-Lung02 ↗